spironolactone has been researched along with doxazosin in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (25.00) | 29.6817 |
| 2010's | 17 (70.83) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Baldó, E; Costa, JA; González, C; Pascual, JM; Pérez-Lahiguera, F; Rodilla, E | 1 |
| Barrios, V; Escobar, C | 1 |
| Brown, MJ; Caulfield, MJ; Cruickshank, JK; Ford, I; MacDonald, TM; Mackenzie, I; McInnes, G; Morant, S; Padmanabhan, S; Salsbury, J; Sever, P; Webb, DJ; Williams, B | 1 |
| Bakris, GL; Sternlicht, H | 1 |
| Huynh, K | 1 |
| Widimský, J | 1 |
| Rosenberg, M; Stephens, E | 1 |
| Divisón Garrote, JA; Escobar Cervantes, C | 1 |
| Boutari, C; Doumas, M; Imprialos, K; Karagiannis, A; Stavropoulos, K | 1 |
| Douma, S; Gavriilaki, E; Gkaliagkousi, E; Triantafyllou, A | 1 |
| Dale, A; Goldacre, B; Hartley, P | 1 |
| Brown, MJ; MacDonald, TM; Morant, SV; Williams, B | 1 |
| Kaysin, A; Mounsey, A | 1 |
| Allan, GM; Garrison, S; Turgeon, R | 1 |
| Casagrande, ML; Cruickshank, JK; Faconti, L; Govoni, V; Mills, CE; Morant, SV; Webb, AJ | 1 |
| Brown, MJ; Caulfield, MJ; Cruickshank, JK; Ford, I; MacDonald, TM; Mackenzie, IS; McInnes, GT; Morant, SV; Padmanabhan, S; Salsbury, J; Sever, P; Webb, DJ; Williams, B | 1 |
| Abu-Abeid, S; Aizpuru, A; Arriaga, S; Baranska, M; Barba de la Rosa, AP; Bunce, M; Carothers, MA; Casas-Flores, S; Costantino, M; Cruickshank, JK; Czamara, K; Drzayich Antol, D; Eldar, SM; Esquivel-González, S; Faconti, L; Gamble, DA; Gao, D; Gómez-Hernández, N; Govoni, V; Gu, H; Guo, J; Hanaoka, H; Haruyama, H; Hazzan, D; Hopson, S; Hua, H; Iso, T; Ji, M; Jiang, B; Kaczor, A; Karnas, E; Khoury, R; Kong, F; Kou, Y; Kurabayashi, M; Lahat, G; Li, X; Liang, X; Lin, J; Liu, S; Liu, X; Majka, Z; Matsui, H; Matsui, M; Meves, JM; Michael, T; Mills, CE; Morant, S; Nachmani, I; Negishi, K; Nevo, N; Niu, L; Palomo-Briones, R; Pan, W; Parikh, A; Peterson, ME; Putri, M; Renda, A; Rishniw, M; Shao, CH; Stein, A; Stemkowski, S; Sun, H; Sun, X; Sunaga, H; Syamsunarno, MRAA; Tanaka, R; Tang, R; Tu, J; Umbarawan, Y; Waldman Casebeer, A; Wang, W; Wang, X; Wang, XY; Wang, Y; Webb, AJ; Wojcik, T; Wu, YJ; Xia, X; Xie, D; Xue, M; Yamaguchi, A; Yang, Y; Ying, HM; Yokoyama, T; Zhan, LX; Zhang, B; Zhang, L; Zhang, Q; Zhang, Y; Zhong, Y; Zhou, F; Zuba-Surma, EK; Zuo, D | 1 |
| Doumas, M; Imprialos, KP; Kallistratos, MS; Manolis, AJ | 1 |
3 review(s) available for spironolactone and doxazosin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Three drugs and still hypertensive: what's left?
Topics: Antihypertensive Agents; Bisoprolol; Blood Pressure; Doxazosin; Drug Therapy, Combination; Humans; Hypertension; Potassium; Spironolactone | 2016 |
Recent advances in understanding and managing resistant/refractory hypertension.
Topics: Antihypertensive Agents; Bisoprolol; Catheters; Clinical Trials as Topic; Clonidine; Denervation; Doxazosin; Humans; Hypertension; Kidney; Spironolactone | 2020 |
5 trial(s) available for spironolactone and doxazosin
| Article | Year |
|---|---|
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; Cross-Over Studies; Double-Blind Method; Doxazosin; Female; Humans; Hypertension; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Spironolactone; Treatment Outcome | 2015 |
[PATHWAY-2 Study: spironolactone vs placebo, bisoprolol and doxazosin to determine optimal treatment of resistant hypertension. Spironolactone high effective in lowering blood pressure in drug resistant hypertension].
Topics: Antihypertensive Agents; Bisoprolol; Blood Pressure; Diuretics; Doxazosin; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Spironolactone | 2015 |
PURLs: Resistant hypertension? Time to consider this fourth-line drug.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bisoprolol; Doxazosin; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Spironolactone; Treatment Outcome | 2016 |
Reducing Arterial Stiffness Independently of Blood Pressure: The VaSera Trial.
Topics: Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Doxazosin; Humans; Nitrates; Pulse Wave Analysis; Spironolactone; Treatment Outcome; Vascular Stiffness | 2017 |
Topics: Adult; Aged; Animals; Astrocytes; Bariatric Surgery; Beta vulgaris; Bioreactors; Biotechnology; Blood Pressure; Body Mass Index; Cat Diseases; Cats; CD36 Antigens; Cell Cycle; Cell Line; Chitinases; Cohort Studies; Comorbidity; Cytokines; Diabetes Mellitus, Type 2; Double-Blind Method; Doxazosin; Echocardiography; Encephalomyelitis, Autoimmune, Experimental; Endothelial Cells; Fasting; Female; Fruit and Vegetable Juices; Gastric Bypass; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Heart; Heart Failure; Homeostasis; Humans; Hypertension; Hypothyroidism; Inflammation; Interleukin-17; Laparoscopy; Length of Stay; Male; Methanol; Mice; Mice, Inbred C57BL; Mice, Knockout; Microbiota; MicroRNAs; Middle Aged; Molecular Imaging; Nitrates; Nutrients; Obesity, Morbid; Pancreatic Neoplasms; Physical Conditioning, Animal; Physical Endurance; Pichia; Placebos; Postoperative Complications; Postoperative Period; Prospective Studies; Pulse Wave Analysis; Radionuclide Imaging; Reoperation; Retrospective Studies; RNA, Messenger; Sequence Analysis, RNA; Signal Transduction; Spectrum Analysis, Raman; Spironolactone; STAT3 Transcription Factor; Suppressor of Cytokine Signaling 3 Protein; Thyroid Gland; Thyrotropin; Thyroxine; Treatment Outcome; Ultrasonography; Vascular Stiffness; Weight Loss | 2018 |
16 other study(ies) available for spironolactone and doxazosin
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Spironolactone and doxazosin treatment in patients with resistant hypertension.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Diuretics; Doxazosin; Drug Resistance; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Retrospective Studies; Spironolactone; Treatment Outcome | 2009 |
Resistant hypertension. What is the best approach?
Topics: Antihypertensive Agents; Doxazosin; Drug Resistance; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Spironolactone; Vasodilator Agents | 2009 |
Spironolactone for resistant hypertension--hard to resist?
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Doxazosin; Female; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2015 |
Hypertension: PATHWAY to improving the treatment of drug-resistant hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Doxazosin; Female; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2015 |
ACP Journal Club. In resistant hypertension, add-on spironolactone reduced SBP more than placebo, doxazosin, or bisoprolol over 12 wk.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Doxazosin; Female; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2016 |
[Spironolactone versus placebo, bisoprolol and doxazosin to determine the optimal treatment for drug-resistant hypertension].
Topics: Antihypertensive Agents; Bisoprolol; Doxazosin; Drug Therapy, Combination; Humans; Hypertension; Spironolactone | 2016 |
PATHWAY-2: spironolactone for resistant hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Doxazosin; Female; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2016 |
PATHWAY-2: spironolactone for resistant hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Doxazosin; Female; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2016 |
PATHWAY-2: spironolactone for resistant hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Doxazosin; Female; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2016 |
PATHWAY-2: spironolactone for resistant hypertension - Authors' reply.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Doxazosin; Female; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2016 |
Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies.
Topics: Aldosterone; Amiloride; Antihypertensive Agents; Bisoprolol; Blood Pressure; Doxazosin; Female; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Randomized Controlled Trials as Topic; Spironolactone | 2018 |